COVID-19 vaccine hesitancy up for racial, ethnic minority healthcare workers
Aug 30, 2021
Vaccine hesitancy was highest among Black and Hispanic or Latino healthcare workers; concerns include side effects and the newness of the vaccine.
30 percent of hospital-based healthcare personnel unvaccinated
Nov 22, 2021
Vaccination coverage was highest among HCP in children’s hospitals, followed by those in short-term acute care hospitals, long-term acute care hospitals, and critical access hospitals (77, 70.1,...
No change found in pattern of adverse events after third COVID-19 shot
Sep 30, 2021
Of the 12,591 individuals who completed a health check-in for all three doses, 79.4 and 74.1% reported local or systemic reactions, respectively.
Many US seniors do not intend to vaccinate against RSV
Mar 13, 2024
The primary reasons for vaccine hesitancy include lack of necessity, concerns about side effects and safety, and lack of information.
2023 to 2024 seasonal influenza vaccine effective for reducing risk
Feb 29, 2024
Vaccine effectiveness against influenza-linked outpatient visits ranged from 33 to 49%, and against hospitalization it ranged from 41 to 44% among adults.
Adverse events after BNT162b2 do not differ for cancer patients
Feb 08, 2022
Among patients with cancer, pain at the injection site was less likely after dose 1 for those receiving active treatment.
Simultaneous flu vaccine, COVID-19 booster safe
Jul 21, 2022
Systemic reactions generally were mild and were slightly more likely among those receiving both vaccines compared with the COVID-19 mRNA booster alone.
Immunoglobulin G spike receptor binding domain antibody levels were similar after the primary series and booster dose.
mRNA-1273 continues to be efficacious at five months
Sep 27, 2021
The efficacy of mRNA-1273, the Moderna vaccine, was 93.2% for preventing COVID-19 illness and 98.2% for preventing severe COVID-19.
Effectiveness of Ad26.COV2.S vaccine stable for six months
Mar 22, 2022
A single dose of the Johnson & Johnson vaccine was 74% and 81% effective for preventing COVID-19 infection and hospitalizations, respectively, in the U.S. before and during delta variant surge.